生命科学资讯

Bayer continues trimming workforce; AnaptysBio's spinoff is named

BIO chief still backs FDA's Makary despite 'head-scratcher' decisions

Sanofi licenses Sino Biopharm’s transplant drug for $135M upfront

UCB boards T cell engager train in $60M upfront deal with Antengene

Blackstone to support Teva on Sanofi-partnered TL1A with $400M

Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant

Old school healthcare is warming up to tech

Prime Medicine reverses course to seek FDA approval of shelved therapy

After years of dispute with FDA, Vanda will get a public hearing for jet lag drug

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

FDA explains how some copycat drugs can still win three years of exclusivity

EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up

Theravance ends R&D, lays off 50% of workers after Phase 3 fail

Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

CMS' Chris Klomp on what it will take for AI to succeed in healthcare

Esperion to buy Corstasis and its nasal spray for edema for $75M upfront

Two more members added to ACIP ahead of March meeting

United Therapeutics to take pulmonary hypertension drug to FDA for approval